Loading people...
Claire Leurent is the Managing Director at AbbVie Ventures in Cambridge, Massachusetts, where she identifies and invests in novel therapeutics aligned with the firm's core research interests. She brings over 14 years of experience in pharmaceutical drug development and corporate venture investing, having previously served as a Principal at Johnson & Johnson Innovation for three years. Earlier in her career, she led clinical development teams through proof-of-concept studies at Pfizer, and recently completed an eight-month residency with the National Institutes of Health Seed program. Leurent holds a doctorate in molecular and cellular biology from the Institute of Genetics, Molecular and Cellular Biology and a Master of Business Administration from MIT Sloan. Her current investment focus spans early-stage biotechnology companies developing small molecules, cell therapies, and artificial intelligence applications across oncology, immunology, neuroscience, and eye care.
Claire Leurent serves as a Principal at Johnson & Johnson Innovation, a pivotal role within one of the world's leading healthcare companies. In this capacity, she is instrumental in identifying, evaluating, and executing strategic investments in early-stage healthcare companies. Her work is central to Johnson & Johnson's commitment to external innovation, seeking out promising startups and technologies that have the potential to address significant unmet medical needs and improve global health outcomes. As a key member of the Johnson & Johnson Innovation team, Claire helps to foster a vibrant ecosystem of collaboration between emerging companies and the vast resources of Johnson & Johnson.
Claire Leurent's investment focus at Johnson & Johnson Innovation is broad yet strategically aligned with the company's diverse portfolio. She actively seeks out opportunities across various segments of healthcare, including pharmaceuticals, medical devices, consumer health, and digital health solutions. Specific therapeutic areas of interest often encompass oncology, immunology, neuroscience, cardiovascular and metabolic diseases, and infectious diseases. Beyond specific disease states, Claire also evaluates innovative platforms and technologies that can disrupt existing paradigms, such as advanced diagnostics, surgical technologies, and novel drug delivery systems. Her objective is to identify companies that are not only scientifically sound but also possess strong commercial potential and a clear path to making a meaningful impact on patients' lives.
While specific details of Claire Leurent's early career are not publicly detailed, her role as a Principal at Johnson & Johnson Innovation suggests a robust background in both science and business. Professionals in such positions typically possess a strong foundation in life sciences, often complemented by advanced degrees in scientific disciplines, business administration, or finance. This blend of scientific acumen and strategic business insight is crucial for evaluating complex healthcare technologies and understanding market dynamics. Her expertise likely includes deep analytical skills, due diligence capabilities, and a keen understanding of the venture capital landscape within the life sciences sector. Claire's career trajectory reflects a dedication to fostering innovation and bringing transformative healthcare solutions from concept to reality.
Through her work, Claire Leurent contributes significantly to Johnson & Johnson's mission of improving human health. She is involved in forging partnerships that provide emerging companies with not only capital but also strategic guidance, access to J&J's scientific expertise, and global market reach. While specific investment names are often confidential, her involvement underscores Johnson & Johnson Innovation's commitment to being a leading investor in the healthcare startup ecosystem. Claire's vision aligns with identifying the next generation of healthcare breakthroughs, ensuring that Johnson & Johnson remains at the forefront of medical innovation. Her efforts are vital in shaping the future of medicine and patient care worldwide.
Claire Leurent is a Principal at Johnson & Johnson Innovation, where she focuses on identifying and investing in early-stage healthcare companies. She plays a crucial role in advancing strategic innovation for Johnson & Johnson.
Claire Leurent invests in a wide range of early-stage healthcare companies, including those in pharmaceuticals, medical devices, consumer health, and digital health. Her focus areas align with Johnson & Johnson's strategic interests, such as oncology, immunology, and neuroscience.
Claire Leurent works as a Principal at Johnson & Johnson Innovation, the venture capital and external innovation arm of Johnson & Johnson.
